A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Evofosfamide (Primary) ; Ipilimumab (Primary)
- Indications Head and neck cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 13 Jun 2017 According to a Threshold Pharmaceuticals media release, first patient has been dosed in the trial at the University of Texas MD Anderson Cancer Center.
- 10 May 2017 Status changed from not yet recruiting to recruiting.
- 27 Mar 2017 Status changed from planning to not yet recruiting.